Pharmacokinetics of camptothecins administered orally

Annals of the New York Academy of Sciences

Volumn 803, Issue , 1996, Pages 157-163

  Liehr, Joachim G ^a   Ahmed, Ahmed E ^a   Giovanella, Beppino C ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b St Joseph's Medical Center Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ALKALOID; CAMPTOTHECIN; LACTONE;

ANTINEOPLASTIC ACTIVITY; CONFERENCE PAPER; DRUG DISTRIBUTION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER; MOUSE; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PLASMA;

EID: 0030468448     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb26384.x     Document Type: Conference Paper

References (19)

1. GALLO, R. C., J. WHANG-PENG & R. H. ADAMSON. 1971. Studies on the antitumor activity, mechanism of action and cell cycle effects. J. Natl. Cancer Inst. 46: 789-795.
2. ABBOT, B. J. 1976. Bioassay of plant extracts for anticancer activity. Cancer Treat Rep. 60: 1007-1010.
3. DEWYS, W. D., S. R. HUMPHREYS & A. GOLDIN. 1968. Studies on the therapeutic effectiveness of drugs with tumor weight and survival time indices of Walker 256 carcinosarcoma. Cancer Chemother. Rep. 52: 229-242.
4. WALL, M. E. & M. C. WANI. 1995. Camptothecin and taxol. Discovery to Clinic. Cancer Res. 55: 753-760.
5. LIU, L. F. 1995. Biochemistry of camptothecin, Chapter 1: 9-19. In Camptothecins: New Anticancer Agents. CRC Press: Boca Raton, FL.
6. POTMESIL, M. & B. C. GIOVANELLA. 1995. Preclinical development of 20(S)-camptothecin, 9-aminocamptothecin, and other analogues, Chapter 4: 51-57. In Camptothecins: New Anticancer Agents. CRC Press: Boca Raton, FL.
7. PANTAZIS, P., J. A. EARLY, A. J. KOZIELSKI, J. T. MENDOZA, H. R. HINZ & B. C. GIOVANELLA. 1993. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: Differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res. 53: 1577-1582.
8. PANTAZIS, P., A. J. KOZIELSKI, J. R. MENDOZA, J. A. EARLY, H. R. HINZ & B. C. GIOVANELLA. 1993. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int. J. Cancer 53: 863-871.
9. PANTAZIS, P., H. R. HINZ, J. T. MENDOZA, A. J. KOZIELSKI, L. J. WILLIAMS, J. S. STEHLIN, & B. C. GIOVANELLA. 1992. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res. 52: 3980-3987.
10. GIOVANELLA, B. C., J. S. STEHLIN, M. E. WALL, M. C. WANI, A. W. NICHOLAS, L. F. LIU, R. SILBER & M. POTMESIL. 1989. DNA topoisomerase 1 targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046.
11. HINZ, H. R., N. J. HARRIS, E. A. NATELSON & B. C. GIOVANELLA. 1994. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20-(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs and mice. Cancer Res. 52: 3096-3100.
12. PANTAZIS, P., N. HARRIS, J. MENDOZA & B. C. GIOVANELLA. 1994. Conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human blood cells in vitro. Eur. J Haematol. 53: 246-248.
13. BURKE, T. G. & Z. MI. 1993. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Analyt. Biochem. 212: 285-287.
14. MI, Z. & T. G. BURKE. 1994. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33: 10325-10336.
15. GIOVANELLA, B. C., H. R. HINZ, A. J. KOZIELSKI, J. S. STEHLIN, JR., R. SILBER & M. POTMESIL. 1991. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res. 51: 3052-3055.
16. MUGGIA, F. M., P. J. CREAVEN, H. H. HANSEN, M. H. COHEN & O. S. SELAWRY. 1972. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother. Rep. 56: 515-521.
17. GOTTLIEB, J. A., A. M. GUARINO, J. B. CALL, V. T. OLIVERIO & J. B. BLOCK. 1970. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep. 54: 461-470.
18. STEHLIN, J. S., E. A. NATELSON, H. R. HINZ, B. C. GIOVANELLA, P. D. DE IPOLYI, K. M. FEHIR, T. P. TREZONA, D. M. VARDEMAN, N. J. HARRIS, A. K. MARCEE, A. J. KOZIELSKI & A. RUIZ-RAZURA. 1995. Phase I clinical trial and pharmacokinetics results with oral administration of 20(S)-camptothecin. Chapter 5: 59-65. In Camptothecins: New Anticancer Agents. CRC Press: Boca Raton, FL.
19. 3H]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: Whole-body autoradiographic studies. Cancer Chemother. Pharmacol. In press.